## UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

ttorney Docket No.	240636US0X

First Inventor or Application Identifier | Alexander B. MAURER

ITE NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS

Assignee Name:

1) 4SC AG 2) G2M Cancer Drugs AG

Assignee Address: 1) Am Klopferspitz 19a 82152 Martinsried, GERMANY

2) Georg-Speyer Haus, Paul-Ehrlich-Strasse 42-44, 60596 rankf

1410 d.s. P

Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: Mail Stop Patent Application See MPEP chapter 600 concerning utility patent application contents Alexandria, Virginia 22313 Fee Transmittal Form (e.g. PTO/SB/17) **ACCOMPANYING APPLICATION PARTS** (Submit an original and a duplicate for fee processing) 7. Assignment Papers (cover sheet & document(s)) Specification **Total Sheets** 29 Application Data Sheet. See 37 CFR 1.76 Power of 37 C.F.R. §3.73(b) Statement (when there is an assignee) Attorney 3. Total Sheets 10. English Translation Document (if applicable) 11. 

Information Disclosure ☐ Copies of IDS Citations Statement (IDS)/PTO-1449 4. 

Oath or Declaration **Total Pages** 12. Preliminary Amendment ☐ Newly executed (original or copy) 13. White Advance Serial No. Postcard a. 14. 

Certified Copy of Priority Document(s) Copy from a prior application (37 C.F.R. §1.63(d)) b. (for continuation/divisional with box 17 completed) (if foreign priority is claimed) i. DELETION OF INVENTOR(S) 15. 
Applicant claims small entity status. Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §1.63(d)(2) and See 37 CFR 1.27 1.33(b)16. Other: CD-ROM or CD-R in duplicate, large table or Computer 5. Program (Appendix) Nucleotide and/or Amino Acid Sequence Submission 6. (if applicable, all necessary) b. Specification or Sequence Listing on : i. CD-ROM or CD-R (2 copies); or ii. 

Paper ☐ Statements verifying identity of above copies 17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below: □ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application no.: Prior application information: Examiner: Group Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 18. Amend the specification by inserting before the first line the sentence: ☐ This application is a ☐ Continuation □ Division ☐ Continuation-in-part (CIP) of application Serial No. Filed on This application claims priority of provisional application Serial No. 60/397,663 Filed July 23, 2002 19. CORRESPONDENCE ADDRESS (703) 413-3000 FACSIMILE: (703) 413-2220

Name:	Norman F. Oblon	Registration No.:	24,618
Signature:	FD Vactine	Date:	7/23/03
Name:	Frederick D. Vastine, Ph.D.	Registration No.:	27,013

Docket No.

240636US0X

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTOR(S) Alexander B. MAURER, et al.

SERIAL NO:

**New Application** 

FILING DATE: Herewith

FOR:

NOVEL COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS

## FEE TRANSMITTAL

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

FOR	NUMBER FILED			NUMBER EXTRA	RATE			CALCULATIONS
TOTAL CLAIMS	16 -	20	=	0	х	\$18	=	\$0.00
INDEPENDENT CLAIMS	1 -	3	=	0	x	\$84	=	\$0.00
☐ MULTIPLE DEPENDENT CLAIMS (If applicable) + \$280 =						\$0.00		
■ LATE FILING OF DECLARATION + \$130 =						=	\$130.00	
BASIC FEE							\$750.00	
TOTAL OF ABOVE CALCULATIONS						\$880.00		
☐ REDUCTION BY 50% FOR FILING BY SMALL ENTITY							\$0.00	
☐ FILING IN NON-ENGLISH LANGUAGE				+	\$130	=	\$0.00	
☐ RECORDATION OF ASSIGNMENT					+	\$40	=	\$0.00
						TOTA	\L	\$880.00

☐ Please charge Deposit Account No. <u>15-0030</u> in the amount of

A duplicate copy of this sheet is enclosed.

- A check in the amount of \$880.00 to cover the filing fee is enclosed.
- The Director is hereby authorized to charge any additional fees which may be required for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND. MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Frederick D. Vastine, Ph.D. Registration No. 27,013

7/23/03

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)